Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Wildhagen

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|January 13, 1996
[Serum screening in pregnant women for Down syndrome and open neural-tube defects; testing against the Health Council criteria for genetic screening]M F Wildhagen, G C Christiaens, J D Habbema
British Medical Bulletin|June 15, 1999
Screening for cystic fibrosis and its evaluationM F Wildhagen, L P ten Kate, J D Habbema
BJU International|March 31, 2004
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancerC H Bangma, M F Wildhagen, G Yurdakul, et al.
Human Reproduction (Oxford, England)|June 17, 2010
Sperm DNA integrity in cancer patients before and after cytotoxic treatmentM Smit, N J van Casteren, M F Wildhagen, et al.
Community Genetics|June 5, 2004
Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general populationM F Wildhagen, T A van Os, J J Polder, et al.
Journal of Medical Screening|August 13, 1999
Efficacy of cascade testing for fragile X syndromeM F Wildhagen, T A van Os, J J Polder, et al.
The Journal of Urology|November 4, 2000
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancerA N Vis, M A Noordzij, K Fitoz, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 12, 1998
[Preconception screening of parents and carrier state of cystic fibrosis in the Netherlands: expenses and savings]J B Verheij, H B Hilderink, J G Verzijl, et al.
BJU International|October 27, 2001
Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancerB G Blijenberg, G Yurdakul, B D Van Zelst, et al.
Community Genetics|June 8, 2004
Preconceptional screening of couples for carriers of cystic fibrosis: a prospective evaluation of effects, costs and savings for different mutation detection methodsJ B Verheij, M F Wildhagen, R M Hofstra, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Nederlands Tijdschrift Voor Geneeskunde|January 13, 1996
[Serum screening in pregnant women for Down syndrome and open neural-tube defects; testing against the Health Council criteria for genetic screening]M F Wildhagen, G C Christiaens, J D Habbema
British Medical Bulletin|June 15, 1999
Screening for cystic fibrosis and its evaluationM F Wildhagen, L P ten Kate, J D Habbema
BJU International|March 31, 2004
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancerC H Bangma, M F Wildhagen, G Yurdakul, et al.
Human Reproduction (Oxford, England)|June 17, 2010
Sperm DNA integrity in cancer patients before and after cytotoxic treatmentM Smit, N J van Casteren, M F Wildhagen, et al.
Community Genetics|June 5, 2004
Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general populationM F Wildhagen, T A van Os, J J Polder, et al.
Journal of Medical Screening|August 13, 1999
Efficacy of cascade testing for fragile X syndromeM F Wildhagen, T A van Os, J J Polder, et al.
The Journal of Urology|November 4, 2000
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancerA N Vis, M A Noordzij, K Fitoz, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 12, 1998
[Preconception screening of parents and carrier state of cystic fibrosis in the Netherlands: expenses and savings]J B Verheij, H B Hilderink, J G Verzijl, et al.
BJU International|October 27, 2001
Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancerB G Blijenberg, G Yurdakul, B D Van Zelst, et al.
Community Genetics|June 8, 2004
Preconceptional screening of couples for carriers of cystic fibrosis: a prospective evaluation of effects, costs and savings for different mutation detection methodsJ B Verheij, M F Wildhagen, R M Hofstra, et al.
Pageof 3